<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33984263</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study.</ArticleTitle><Pagination><StartPage>1373</StartPage><EndPage>1382</EndPage><MedlinePgn>1373-1382</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(21)00211-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(21)00211-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Individuals admitted to hospital for COVID-19 might have persisting symptoms (so-called long COVID) and delayed complications after discharge. However, little is known regarding the risk for those not admitted to hospital. We therefore examined prescription drug and health-care use after SARS-CoV-2 infection not requiring hospital admission.</AbstractText><AbstractText Label="METHODS">This was a population-based cohort study using the Danish prescription, patient, and health insurance registries. All individuals with a positive or negative RT-PCR test for SARS-CoV-2 in Denmark between Feb 27 and May 31, 2020, were eligible for inclusion. Outcomes of interest were delayed acute complications, chronic disease, hospital visits due to persisting symptoms, and prescription drug use. We used data from non-hospitalised SARS-CoV-2-positive and matched SARS-CoV-2-negative individuals from 2 weeks to 6 months after a SARS-CoV-2 test to obtain propensity score-weighted risk differences (RDs) and risk ratios (RRs) for initiation of 14 drug groups and 27 hospital diagnoses indicative of potential post-acute effects. We also calculated prior event rate ratio-adjusted rate ratios of overall health-care use. This study is registered in the EU Electronic Register of Post-Authorisation Studies (EUPAS37658).</AbstractText><AbstractText Label="FINDINGS">10&#x2009;498 eligible individuals tested positive for SARS-CoV-2 in Denmark from Feb 27 to May 31, 2020, of whom 8983 (85&#xb7;6%) were alive and not admitted to hospital 2 weeks after their positive test. The matched SARS-CoV-2-negative reference population not admitted to hospital consisted of 80&#x2009;894 individuals. Compared with SARS-CoV-2-negative individuals, SARS-CoV-2-positive individuals were not at an increased risk of initiating new drugs (RD &lt;0&#xb7;1%) except bronchodilating agents, specifically short-acting &#x3b2;2-agonists (117 [1&#xb7;7%] of 6935 positive individuals vs 743 [1&#xb7;3%] of 57&#x2009;206 negative individuals; RD +0&#xb7;4% [95% CI 0&#xb7;1-0&#xb7;7]; RR 1&#xb7;32 [1&#xb7;09-1&#xb7;60]) and triptans (33 [0&#xb7;4%] of 8292 vs 198 [0&#xb7;3%] of 72&#x2009;828; RD +0&#xb7;1% [0&#xb7;0-0&#xb7;3]; RR 1&#xb7;55 [1&#xb7;07-2&#xb7;25]). There was an increased risk of receiving hospital diagnoses of dyspnoea (103 [1&#xb7;2%] of 8676 vs 499 [0&#xb7;7%] of 76&#x2009;728; RD +0&#xb7;6% [0&#xb7;4-0&#xb7;8]; RR 2&#xb7;00 [1&#xb7;62-2&#xb7;48]) and venous thromboembolism (20 [0&#xb7;2%] of 8785 vs 110 [0&#xb7;1%] of 78&#x2009;872; RD +0&#xb7;1% [0&#xb7;0-0&#xb7;2]; RR 1&#xb7;77 [1&#xb7;09-2&#xb7;86]) for SARS-CoV-2-positive individuals compared with negative individuals, but no increased risk of other diagnoses. Prior event rate ratio-adjusted rate ratios of overall general practitioner visits (1&#xb7;18 [95% CI 1&#xb7;15-1&#xb7;22]) and outpatient hospital visits (1&#xb7;10 [1&#xb7;05-1&#xb7;16]), but not hospital admission, showed increases among SARS-CoV-2-positive individuals compared with SARS-CoV-2-negative individuals.</AbstractText><AbstractText Label="INTERPRETATION">The absolute risk of severe post-acute complications after SARS-CoV-2 infection not requiring hospital admission is low. However, increases in visits to general practitioners and outpatient hospital visits could indicate COVID-19 sequelae.</AbstractText><AbstractText Label="FUNDING">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lund</LastName><ForeName>Lars Christian</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallas</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark; Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Epidemiology &amp; Prevention, Statens Serum Institut, Copenhagen, Denmark; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mogensen</LastName><ForeName>Stine Hasling</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Data Analytics Centre, Danish Medicines Agency, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brun</LastName><ForeName>Nikolai Constantin</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Medical Evaluation and Biostatistics, Danish Medicines Agency, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Christian Fynbo</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Reimar Wernich</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potteg&#xe5;rd</LastName><ForeName>Anton</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Electronic address: apottegaard@health.sdu.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2021 Oct;21(10):1335-1336. doi: 10.1016/S1473-3099(21)00225-5</RefSource><PMID Version="1">33984264</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests AP and JH report funds paid to their institution for participation in research projects funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Servier, and LEO Pharma, outside the the current work. LCL reports funds paid to his institution for participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma, outside the current work. HN reports funds paid to their institution for participation in research projects funded by Merck Sharp &amp; Dohme and Novo Nordisk Foundation, outside the current work. The institution of CFC and RWT is involved in studies with funding from various companies as research grants to (and administered by) Aarhus University, outside the current work. AK, SHM, and NCB report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33984263</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pii">S1473-3099(21)00211-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Weekly epidemiological update on COVID-19&#x2014;20. April 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-20-april-2021</Citation></Reference><Reference><Citation>Reilev M, Kristensen KB, Potteg&#xe5;rd A, et al. Characteristics and predictors of hospitalization and death in the first 11&#x2008;122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499657</ArticleId><ArticleId IdType="pubmed">32887982</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7439160</ArticleId><ArticleId IdType="pubmed">32850151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Masciocchi S, Volonghi I, et al. Clinical presentation and outcomes of severe acute respiratory syndrome coronavirus 2-related encephalitis: the ENCOVID multicentre study. J Infect Dis. 2021;223:28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543535</ArticleId><ArticleId IdType="pubmed">32986824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177070</ArticleId><ArticleId IdType="pubmed">32353746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalager-Pedersen M, Lund LC, Mariager T, et al. Venous thromboembolism and major bleeding in patients with COVID-19: a nationwide population-based cohort study. Clin Infect Dis. 2021 doi: 10.1093/cid/ciab003. published online Jan 5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab003</ArticleId><ArticleId IdType="pmc">PMC7929126</ArticleId><ArticleId IdType="pubmed">33400771</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1&#xb7;5&#x2013;6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020;76:405&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716295</ArticleId><ArticleId IdType="pubmed">33273028</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. medRxiv. 2020 doi: 10.1101/2020.12.24.20248802. published online Dec 27. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.24.20248802</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A, Kristensen KB, Reilev M, et al. Existing data sources in clinical epidemiology: the Danish COVID-19 cohort. Clin Epidemiol. 2020;12:875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429185</ArticleId><ArticleId IdType="pubmed">32848476</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen LC, Daasnes C, Thaulow I, Br&#xf8;nnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39(suppl):12&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">21898916</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324:2251&#x2013;2252.</Citation><ArticleIdList><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Poncet-Megemont L, Paris P, Tronchere A, et al. High prevalence of headaches during Covid-19 infection: a retrospective cohort study. Headache. 2020;60:2578&#x2013;2582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436456</ArticleId><ArticleId IdType="pubmed">32757419</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A, Schmidt SAJ, Wallach-Kildemoes H, S&#xf8;rensen HT, Hallas J, Schmidt M. Data resource profile: the danish national prescription registry. Int J Epidemiol. 2017;46:798. 798f.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837522</ArticleId><ArticleId IdType="pubmed">27789670</ArticleId></ArticleIdList></Reference><Reference><Citation>You J, Zhang L, Ni-Jia-Ti MY, et al. Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. J Infect. 2020;81:e150&#x2013;e152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273134</ArticleId><ArticleId IdType="pubmed">32512021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellosta R, Luzzani L, Natalini G, et al. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg. 2020;72:1864&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188654</ArticleId><ArticleId IdType="pubmed">32360679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollstein T, Schulte DM, Schulz J, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab. 2020;2:1021&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">32879473</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayan A, Humphreys BD. SARS-CoV-2 in the kidney: bystander or culprit? Nat Rev Nephrol. 2020;16:703&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487445</ArticleId><ArticleId IdType="pubmed">32929200</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020;79:999&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299653</ArticleId><ArticleId IdType="pubmed">32527868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655913</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt JFH, Hansen AT, Ladefoged SA, S&#xf8;rensen HT, Pedersen L, Adelborg K. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol. 2020;12:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244445</ArticleId><ArticleId IdType="pubmed">32547238</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367</Citation><ArticleIdList><ArticleId IdType="pubmed">31645336</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083&#x2013;3107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MG, Xie D, Tannen RL. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. Pharmacoepidemiol Drug Saf. 2008;17:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">18327857</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kasteren PB, van der Veer B, van den Brink S, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol. 2020;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206434</ArticleId><ArticleId IdType="pubmed">32416600</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Pilotto A, Premi E, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020 9x0.</Citation><ArticleIdList><ArticleId IdType="pubmed">32444493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>